Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1106Carcinoma, Renal Cell 412Urinary Bladder Neoplasms 280Kidney Neoplasms 177Neoplasm Metastasis 134Neoplasms 132Carcinoma, Non-Small-Cell Lung 109Carcinoma, Transitional Cell 108Breast Neoplasms 94Melanoma 90Ovarian Neoplasms 70Lung Neoplasms 67Colorectal Neoplasms 58Pancreatic Neoplasms 49Sarcoma 48Wilms Tumor 41Uterine Cervical Neoplasms 37Head and Neck Neoplasms 37Stomach Neoplasms 36Testicular Neoplasms 33Non-Muscle Invasive Bladder Neoplasms 33Esophageal Neoplasms 33Squamous Cell Carcinoma of Head and Neck 31Neuroblastoma 30Lymphoma, Non-Hodgkin 29Colonic Neoplasms 28Small Cell Lung Carcinoma 27Carcinoma, Hepatocellular 27Urethral Neoplasms 25Triple Negative Breast Neoplasms 23

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hormone Sensitive Prostate Cancer × Genitourinary × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡